Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced it has completed enrollment in the third cohort of patients in the Phase 1b MAD study of RGLS8429 for…
Hansa Biopharma Reaches a Crucial Milestone in Imlifidase Phase 2 Clinical Trial for Guillain-Barré Syndrome
Hansa Biopharma (Nasdaq Stockholm: HNSA), a trailblazer in the world of enzyme technology aimed at rare immunological conditions, proudly announces that enrollment for its phase 2 clinical trial of imlifidase in Guillain-Barré Syndrome (GBS) has been successfully completed. The study’s…